Loading
A phase 1/2 trial of Tislelizumab in renal cell carcinoma and melanoma, run by BeiGene, active and no longer recruiting.
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05661955 by BeiGene, with 113 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2025-05-27. Interventions recorded: BGB-A445, Tislelizumab. Conditions listed: Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma. No results are recorded here; the registry entry is the source.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.